For US Prescribers Only


For US Prescribers Only

Image of a woman with her hair pulled up away from her face with a slight smile.

PERSERIS® is indicated for the
treatment of schizophrenia in adults.

LAI Antipsychotic Therapy for Adults With Schizophrenia

Introduction to Perseris®

  • This program is being presented on behalf of Indivior Inc., in accordance with applicable regulations and guidelines of the US Food and Drug Administration, as well as company policies.
  • The speaker has been compensated by Indivior for presenting this program.
  • All information appearing in this video is the property of Indivior Inc. This information is protected and is not to be photographed, downloaded, or reproduced in any way. It is not to be further disseminated, distributed, shared, or disclosed, in whole or in part, to any other party or person, without the express prior consent of Indivior.
Image of featured speaker, Dr. Henry A. Nasrallah

Dr. Henry A. Nasrallah

Dr. Henry Nasrallah is a professor of psychiatry, neurology, and neuroscience, and director of the Schizophrenia Program at the University of Cincinnati College of Medicine. He has served as chair of psychiatry for 18 years and as associate dean for 4 years. Dr. Nasrallah has published over 900 scientific articles and editorials, as well as 13 books. He is editor-in-chief of 3 journals and has served as president of several organizations. He is a Distinguished Life Fellow of the American Psychiatric Association and a recipient of numerous national and international awards and recognitions.

Image of featured speaker, Dr. Gustavo Alva

Dr. Gustavo Alva

Dr. Gustavo Alva is medical director of ATP Clinical Research in Costa Mesa, California; CEO and founder of Gus Alva, MD, in Costa Mesa and Anaheim, California; medical director, Senior Brain Health at Hoag Hospital in Newport Beach, California; and assistant professor in the Department of Neuroscience at the University of California, Riverside. Dr. Alva is a diplomate of the American Board of Psychiatry and Neurology and a Distinguished Fellow of the American Psychiatric Association.

Image of featured speaker, Dr. Sanjay Gupta

Dr. Sanjay Gupta

Dr. Sanjay Gupta is the chief medical officer of the BryLin Hospital System in Buffalo, New York. He is also the medical director of Endeavor Health Services, a large outpatient clinic with multiple locations that serves severely and persistently ill psychiatric patients in Western New York. Dr. Gupta is on the editorial board of Current Psychiatry, is the deputy editor of Annals of Clinical Psychiatry, and is a board member and former president of the American Academy of Clinical Psychiatrists.

Image of featured speaker, Dr. Cherian Verghese

Dr. Cherian Verghese

Dr. Cherian Verghese is the founder and medical director of Keystone Clinical Studies, LLC in Plymouth Meeting, Pennsylvania, and a clinical assistant professor of psychiatry at Temple University School of Medicine in Philadelphia, Pennsylvania. He has been the principal investigator on more than 130 clinical trials to date and has been instrumental in the FDA approval of medications in more than 10 different indications.


PERSERIS® (risperidone) for extended-release injectable suspension, for subcutaneous use is indicated for the treatment of schizophrenia in adults.



Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. PERSERIS is not approved for the treatment of patients with dementia-related psychosis.

CONTRAINDICATIONS: PERSERIS is contraindicated in patients with a known hypersensitivity to risperidone, its metabolite, paliperidone, or to any of its components. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone or paliperidone.


Cerebrovascular Adverse Reactions: In trials of elderly patients with dementia-related psychosis, there was a significantly higher incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, in patients treated with oral risperidone compared to placebo. PERSERIS is not approved for use in patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported with antipsychotic medications. Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status including delirium, and autonomic instability (see full Prescribing Information). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If NMS is suspected, immediately discontinue PERSERIS and provide symptomatic treatment and monitoring.

Tardive Dyskinesia (TD) may develop in patients treated with antipsychotic drugs. The risk of developing TD and likelihood that it will become irreversible are believed to increase with treatment duration and total cumulative dose. TD can develop after relatively brief treatment periods even at low doses, or after treatment discontinuation. Elderly patients, especially elderly women, appear to be at increased risk, but it is impossible to predict which patients will develop TD. Therefore, PERSERIS should be prescribed in a manner that is most likely to minimize the occurrence of TD. Discontinue treatment if clinically appropriate.

Metabolic Changes that may increase cardiovascular/cerebrovascular risk, have been associated with atypical antipsychotics (APs).

  • Hyperglycemia and Diabetes Mellitus (DM), in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with APs, including risperidone. Patients with DM who are started on atypical APs, including PERSERIS, should be monitored regularly for worsening of glucose control. Patients at risk for DM (e.g., obesity, family history of diabetes) who are starting treatment with atypical APs, including PERSERIS, should undergo fasting blood glucose (FBG) testing at the beginning of treatment and periodically while treated. Any patient treated with atypical APs, including PERSERIS, should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical APs, including PERSERIS, should undergo FBG testing. In some cases, hyperglycemia has resolved when risperidone was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of risperidone.
  • Dyslipidemia has been observed in patients treated with atypical APs. When initiating PERSERIS, obtain a fasting lipid profile and monitor periodically during treatment.
  • Weight Gain has been observed with atypical AP use. Monitoring weight is recommended.

Hyperprolactinemia: Risperidone elevates prolactin levels, and the elevation persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents. Hyperprolactinemia may inhibit reproductive function in female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating drugs. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in females and males.

Orthostatic Hypotension and Syncope: Risperidone may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, particularly at treatment initiation, re-initiation, or dose increase. Use with particular caution in patients with known cardiovascular disease, cerebrovascular disease, and conditions which predispose patients to hypotension, and in the elderly and patients with renal or hepatic impairment. Monitor such patients and consider a dose reduction if hypotension occurs.

Falls: Somnolence, postural hypotension, motor instability, and sensory instability have been reported with the use of antipsychotics, including PERSERIS, which may lead to falls, and consequently, fractures or other fall-related injuries. Assess the risk of falls when initiating treatment and recurrently during treatment.

Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotic agents, including risperidone. In patients with history of clinically significant low white blood count (WBC) or absolute neutrophil count (ANC), or history of drug-induced leukopenia or neutropenia, perform a complete blood count frequently during the first few months of therapy. Consider discontinuation at the first sign of clinically significant decline in WBC in the absence of other causative factors. Monitor patients with clinically significant neutropenia for fever or other symptoms/signs of infection; treat promptly if such symptoms/signs occur. Discontinue PERSERIS in patients with ANC <1000/mm3 and follow WBC until recovery.

Potential for Cognitive and Motor Impairment: Antipsychotics including PERSERIS may cause somnolence and impair judgment, thinking, and motor skills. Caution patients about operating machinery, including motor vehicles, until they are reasonably certain PERSERIS does not affect them adversely.

Seizures were observed in risperidone studies in adults with schizophrenia. PERSERIS should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.

Dysphagia: Esophageal dysmotility and aspiration can occur. Use cautiously in patients at risk for aspiration.

Priapism has been reported with other risperidone products. Severe priapism may require surgical intervention.

Body Temperature Regulation: Atypical antipsychotics may disrupt the body’s ability to reduce core body temperature. Use with caution during strenuous exercise, exposure to extreme heat, dehydration, or when taking anticholinergic medications.

ADVERSE REACTIONS: The most common adverse reactions in a clinical trial (≥ 5% and greater than placebo) were increased weight, constipation, sedation/somnolence, pain in extremity, back pain, akathisia, anxiety, and musculoskeletal pain. The most common injection site reactions (≥ 5%) were injection site pain and erythema. This is not a complete list of potential adverse events. Please see the full Prescribing Information for a complete list.


  • Carbamazepine and other strong CYP3A4 inducers decrease risperidone plasma concentration.
  • Fluoxetine, paroxetine, and other strong CYP2D6 inhibitors increase risperidone plasma concentration.
  • Use with other CNS drugs or alcohol may increase nervous system disorders.
  • PERSERIS may enhance hypotensive effects of hypotensive agents.
  • PERSERIS may antagonize the pharmacologic effects of dopamine agonists.
  • Dosage change in PERSERIS or methylphenidate may increase risk of extrapyramidal symptoms.


Pregnancy: PERSERIS may cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare professional if they become or intend to become pregnant during treatment with PERSERIS. Patients exposed to PERSERIS during pregnancy may be registered with the National Pregnancy Registry for Atypical Antipsychotics (1-866-961-2388 or

Lactation: Infants exposed to risperidone through breastmilk should be monitored for excess sedation, failure to thrive, jitteriness, and extrapyramidal symptoms.

Pediatric Use: Safety and effectiveness of PERSERIS have not been established in pediatric patients.

Renal or Hepatic Impairment: Carefully titrate on oral risperidone up to at least 3 mg before initiating treatment with PERSERIS at a dose of 90 mg.

Patients with Parkinson’s Disease or dementia with Lewy Bodies can experience increased sensitivity to risperidone. Manifestations can include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with NMS.

To report a pregnancy or side effects associated with taking PERSERIS or any safety related information, product complaint, request for medical information, or product query, please contact or 1-877-782-6966.

See full Prescribing Information including BOXED WARNING.


Indivior logo
Site MapPrivacy PolicyPrivacy Policy and Notice for California ResidentsWAC Pricing DisclosureTerms of UseAccessibilityContact Us

PERSERIS is manufactured for Indivior Inc., North Chesterfield, VA 23235.

© 2024 Indivior UK Limited | INDIVIOR®, PERSERIS®, and INSUPPORT® are registered trademarks of Indivior UK Limited | All Rights Reserved.

P-RAG-US-00587, P-RAG-US-00589

Intended for US audiences.